FLT3 and acute myeloid leukemia: In our study we examined the second-generation Flt3 inhibitor quizartinib, which has shown a high potency in the treatment of AML either as a single agent or in combination with conventional chemotherapy regimens [43], but also potentially relevant cardiotoxicity in clinical trials [10].